Convergence and Personalized Medicine
Greg Yap is Senior Vice President and Lifecycle Leader for Advanced Staining Assays at Ventana Medical Systems. In this role, Greg is responsible for Ventana’s 450 million dollar cancer diagnostic testing business. Ventana’s tests are the market leaders and are used to help guide treatment for over 6 million cancer patients each year worldwide. Previously, Greg was Chief Operating Officer at Cellective Dx, a circulating tumor cell company, and held multiple senior operating roles at Affymetrix.
From Bioscience to Biobusiness Success
Dr. Robert Bowser was recruited to the Barrow Neurological Institute and St. Joseph’s Hospital & Medical Center to direct an ALS research center using philanthropic support from Mr. Ira Fulton. He arrived to the Phoenix area in August of last year after 18 years on the faculty at the University of Pittsburgh School of Medicine. Dr. Bowser’s research focuses on biomarkers of neurologic disease and he will describe how success in his academic research has also led to success in the world of biotechnology.
Ground Broken for University of Arizona Cancer Center in Phoenix
Ground Broken for University of Arizona Cancer Center in Phoenix Ground was officially broken on the new University of Arizona Cancer Center (UACC) at St. Joseph's Hospital and Medical Center/Dignity Health outpatient facility in downtown Phoenix in February, 2013. Located on the Phoenix Biomedical Campus at 625 N. Sixth St., on the northwest corner of Fillmore and Seventh streets, the center is expected to be open in 2015. Follow the project's construction progress at www.phoenixcancercenter.org
Flagship Biosciences - AZBio Company of the Year | 2012 Finalist
Flagship Biosciences provides quantitative tissue analysis services for pharmaceutical and medical device development. Flagship offers a broad range of tissue assessment options, achieved through a diverse set of approaches. Flagship Biosciences provides tissue analysis solutions to over sixty biotech, pharmaceutical, and medical device clients, with global programs in place for tissue-based companion diagnostics with three of the largest pharmaceutical companies in the world. Their sales grew 400% in 2011, and are on track to triple again in 2012. Flagship scientists published seven peer-reviewed articles in 2011, and filed 4 patent applications during the year. However, the largest development for Flagship was the acquisition of a histology and immunohistochemistry laboratory during the close 2011 which has added tissue procurement to complete their tissue-based analysis operations. Finally, the company’s image analysis technology won a best poster award at the Pathology Visions 2011 conference in San Diego, and a best presentation award at the Pathology Informatics 2011 meeting in Pittsburgh The company is currently working on a medical device spinout of their existing operations and expansion into Phoenix later this year. Committed to growing not only the company but also Arizona’s bioscience talent pool, the company currently utilizes many students from Northern Arizona University. Flagship Biosciences was honored in 2011 with the 2011 AZBio Fast Lane Award .
2012 Bioscience Company of the Year - Cord Blood Registry
The first cord blood sample ever saved by a family belonged to the son of CBR's Scientific Director. Two decades later, CBR (Cord Blood Registry) is the largest, most experienced stem cell bank, entrusted by families worldwide. Thanks to expecting families like yours, more than 400,000 children have newborn stem cells saved with CBR. As you decide what's best for your family, it's important to understand the CBR difference in quality and experience. CBR has banked more stem cells than any other family bank and has the most experience helping families use their cord blood for medical treatments. In October 2012, CBR was named the Arizona Bioscience Company of the Year.
Arizona Pioneer Thomas M. Grogan, MD
Thomas M. Grogan, M.D., Founder of Ventana and SVP, Medical Affairs of Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, receives the AZBio Pioneer Award for Lifetime Achievement at the 2013 AZBio Awards on October 10, 2013. Dr. Grogan was a pathologist and professor at the University of Arizona when in the mid 1980’s he and a small team set out to challenge the limitations of the then current standards and processes for cancer pathology. What was to become the company’s first digital pathology instrument evolved from Grogan’s notes on a yellow pad into the BenchMark IHC/ISH staining platforms. Under Grogan’s leadership, Ventana was founded in 1987, went public in 1996, and was acquired by Roche for $3.4 billion in 2008. Over the last 25 years, Ventana has grown to become a global leader in developing and manufacturing tissue-based diagnostic instruments and tests focused on the detection of cancer. Ventana employees continue to pursue the same deeply rooted mission of innovating diagnostic testing and enabling personalized healthcare to improve the lives of all patients afflicted with cancer worldwide. Dr. Grogan has made it his personal mission to make life better for the millions of patients who battle cancer each day. His passion and dedication are infectious and has spread across the company that he and his team built. Through their efforts they have revolutionized the field of cancer diagnostics and are pioneering new roads in the field of personalized healthcare.”
Raymond L. Woosley, MD, PhD - 2012 AZBio Pioneer
Raymond L. Woosley earned a Ph.D. in Pharmacology from the University of Louisville and an M.D. from the University of Miami. He began his career as the first scientist in the US operations for Glaxo, now known as GlaxoSmithKline. Dr. Woosley specialized in Internal Medicine and Clinical Pharmacology at Vanderbilt University where he rose to the rank of Professor of Medicine. At Georgetown University he served as Chairman of the Department of Pharmacology and in 2000 was appointed Associate Dean for Clinical Research. In 2001 he became Vice President for Health Sciences at the University of Arizona and Dean of the College of Medicine. In January of 2005 he assumed the position of President of The Critical Path Institute (C-Path), a non-profit corporation formed by the Food and Drug Administration, SRI, International and the University of Arizona to accelerate the development of safe innovative medicines. Since 1999, he has directed one of seven federally-funded (Agency for Healthcare Research and Quality) Centers for Education and Research on Therapeutics (CERT).Under Dr. Woosley’s leadership, C-Path (the Critical Path Institute) orchestrated the acceleration of medical product development through a unique collaborative process among industry, academia, and the FDA. Our collaborations among 6 global consortia, 1000+scientists, and 41 companies has already produced these notable successes: First preclinical safety biomarkers (7) qualified by the FDA, EMA, and PMDA (the Japanese counterpart) First CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard First and largest open database of CDISC aggregated clinical trial data for Alzheimer’s disease (6,100 patients and 22 clinical trials) Read more First drug-disease trial model & clinical trial simulation tool submitted and under review by the FDA First imaging biomarker for trial enrichment qualified by the EMA Dr. Woosley’s research has investigated the basic and clinical pharmacology of drugs for the treatment of arrhythmias and the cardiac toxicity of drugs, and has been published in over 260 publications. His research discovered the mechanism of the toxicity of the antihistamine Seldane®. He is the recipient of the Rawls-Palmer Award from the American Society of Clinical Pharmacology and Therapeutics for his contributions to medicine and the FDA Commissioner’s Special Citation for his work to advise the agency on the toxicity of dietary supplements containing ephedra. Dr. Woosley is a Past-President of the Association for Medical School Pharmacology and the American Society for Clinical Pharmacology and Therapeutics. He has served on numerous boards including the US Pharmacopeia. He is a member of the Biodesign Institute at Arizona State University. As a member of the University of Arizona’s Sarver Heart Center and Bio5 Institute, he conducts research on the prevention of adverse drug interactions.
AZBio and SynCardia on ABC15
By: Christina Estes ABC15 Tucson-based SynCardia Systems was among the companies showcased at the annual AZ Bio Expo.It’s a chance for bioscience and technology companies to learn more about funding opportunities and hear success stories.According to the Arizona BioIndustry Association, our state is getting more federal funding for research and seeing higher job growth in the bioscience industry compared to the national average.“Tucson and Arizona are the international headquarters for the world’s only total artificial heart,” said Don Isaacs, SynCardia vice president of communications. “They replace the exact same parts of the heart as if you had a heart transplant.”The SynCardia heart is made in Arizona using bio-compatible material also made here. Isaacs says they have 82 employees in Arizona and about 80 people currently using the heart. The device is considered a bridge for people awaiting a transplant or a life saver for those who will not get transplants due to age or medical conditions.“There’s only 2,200 hearts available per year in the United States and the level of donors has been the same for the last twenty years,” Isaacs said.SynCardia is also undergoing FDA clinical trials for the world’s first wearable power supply for their temporary artificial heart. ©2007 The E.W. Scripps Co. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. (Republished with permission from ABC15) Read more: http://www.abc15.com/dpp/news/region_southeast_valley/tempe/Arizona-company-SynCardia-Systems-makes-worlds-first-total-temporary-artificial-heart#ixzz2X99ewU3x
Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury , lecturing around the United States and the world. Now he joined Phoenix Children's to expand a program that surpasses the typical model of pediatric care. For some, it's playing a musical instrument. For others, it's painting. But for P. David Adelson, MD, FACS, FAAP, the director of the Hospital's Barrow Neurological Institute and chief of neurosurgery, his passion is a bit atypical. "My hobby is neuroscience," he says. "The heart's a pump, the kidney's a filter – those are all simple functions which are there to support who we are and what we do." But the brain controls it all, he says. "I just looked at the brain and neurosciences as the next frontier; studying something of which I would never get bored." Dr. Adelson has been recognized as one of the foremost experts on pediatric head injury clinical management, lecturing around the United States and the world. He has been published in numerous medical and scientific journals defining "state-of-the art" in the care of children with traumatic brain injuries. The path to Phoenix Children's Hospital Dr. Adelson came to Phoenix in January from Pittsburgh, where he served as the A. Leland Albright Endowed Professor of Neurosurgery/Pediatric Neurosurgery at Children's Hospital of Pittsburgh and Vice Chairman, (Research) at the University of Pittsburgh School of Medicine , one of the most prominent neurosurgical departments in the country.
2012 Fast Lane Award Winner - the Critical Path Institute
With both drug development costs and healthcare costs at record heights, how can we drive innovation and lifesaving discoveries down the path faster. That is the question the team at the Critical Path Institute (C-Path) asks every day. Critical Path Institute , a healthcare change agent and leading center of excellence for collaborative scientific innovation, was formed with visionary support from the State of Arizona, UA, Science Foundation Arizona, FDA and the community at large. Its mission: to improve human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. There is no other entity in the country that does what C-Path does. C-Path Milestones and “firsts” include: 1st preclinical safety biomarkers (7) qualified by FDA and its counterparts in Europe and Japan – biomarkers used to detect drug-induced kidney injury earlier and more precisely. 1st CDISC (Clinical Data Interchange Standards Consortium) therapeutic area data standard enables aggregating and easier FDA review of Alzheimer’s clinical trial data. 1st and largest open database of CDISC aggregated Alzheimer’s clinical trial data (6,100 patients, 22 clinical trials) enabling scientists to look for means to detect disease earlier and understand disease progression based on age, sex, genotypes. 1st drug-disease trial model and clinical trial simulation tool submitted/under review by FDA – model enables scientists to better design Alzheimer’s clinical trials. 1st imaging biomarker for trial enrichment qualified by EMA – biomarker used to select patients in very early stages of Alzheimer’s for inclusion in clinical trials. C-Path brings together stakeholders to create what no one company, university, or government agency could do alone: 6 global consortia with 1,000 scientists, 41 companies, government agencies, patient groups, and academia to collaborate on “tools” to help drug development and focus on drug safety, drug effectiveness, diseases of the brain, developing new imaging biomarkers, and testing drug combinations. C-Path’s collaborative work is just beginning to translate knowledge of disease and human physiology into safe and effective therapies.